Colon-Otero, Gerardo
Van Wier, Scott A.
Ahmann, Greg J.
Braggio, Esteban
Albertie, Monica L.
Weis, Jennifer A.
Ailawadhi, Sikander
Cerhan, James R.
Vishnu, Prakash
Jorgensen, Matthew S.
Foran, James M.
Thomas, Colleen S.
Fonseca, Rafael
Funding for this research was provided by:
National Center for Research Resources (1 UL1 RR023150)
National Cancer Institute (P50-CA01508)
National Cancer Institute (CA 90297052)
Mayo Clinic Office of Health Disparities Research
Article History
Received: 31 August 2016
Accepted: 25 September 2016
First Online: 12 October 2016
Compliance with Ethical Standards
: This project was part of a Mayo Clinic Institutional Review Board-approved translational cancer research pilot study aimed at increasing awareness on the importance of cancer research among the Northeast Florida AA population.
: Dr. Colon-Otero discloses research funding with Novartis pharmaceuticals. Dr. Alawadhi discloses that he is a consultant for Novartis, Amgen, Pharmacyclics, and Takeda pharmaceuticals. Dr. Fonseca has received a patent for the prognostication of MM based on genetic categorization by FISH of the disease. He has a patent application pending for the use of calcium isotopes as biomarkers for bone metabolisms (primary site and investigators, Arizona State University). He has received consulting fees from Celgene, BMS, Bayer, Novartis, Sanofi, Janssen, Millennium, a Takeda Company, and AMGEN. He is also a member of the Scientific Advisory Board of Applied Biosciences.Mr. Van Wier, Mr. Ahmann, Dr. Braggio, Ms. Albertie, Ms. Weis, Dr. Cerhan, Dr. Vishnu, Mr. Jorgensen, Dr. Foran, and Ms. Thomas declare that they have no conflict of interest.
: This paper was funded by the Mayo Clinic Office of Health Disparities Research, Mayo Clinic CTSA grant (NCRR/NIH Grant Number 1 UL1 RR024150), the Mayo Clinic Cancer Center (NCI grant number P50-CA01508), and Active SPORE CA 90297052 grant.
: This paper was presented at AACR Cancer Disparities Meeting, Atlanta, GA, USA, 2015.